Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at UT Southwestern Medical Center

Sites in Dallas, TX

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 4:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1262
Shown on this page
12
Current sort
Recently updated
Campus scope
UT Southwestern Medical Center, Dallas, TX
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within UT Southwestern Medical Center, Dallas, TX. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 577–588 of 1,262 matching trials with a site at UT Southwestern Medical Center, Dallas, TX.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 3 Interventional

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

NCT05338970
Site status not listed — check the official record
View directory record Official record
Conditions
Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion
Interventions
Patritumab Deruxtecan, Platinum-based chemotherapy
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
586 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
23
States / cities
Anchorage, Alaska • Springdale, Arkansas • Duarte, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 31, 2026, 4:36 AM EDT
Recruiting Phase 2 Interventional

Digoxin Medulloblastoma Study

NCT06701812
Status at this site: Recruiting
View directory record Official record
Conditions
Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH
Interventions
Digoxin
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
12 Months to 30 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
17
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 31, 2026, 4:36 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Augmented Reality-Cardiopulmonary Resuscitation Support for Pediatric Resuscitation

NCT07778823
Status at this site: Recruiting
View directory record Official record
Conditions
Cardiac Arrest (CA), Pediatric Cardiac Arrest (Simulated), Cardiopulmonary Resuscitation (CPR)
Interventions
AR-CPR
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
7
States / cities
St. Petersburg, Florida • Baltimore, Maryland • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 31, 2026, 4:36 AM EDT
Recruiting Not applicable Interventional

HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial

NCT04743765
Status at this site: Active, not recruiting
View directory record Official record
Conditions
Hip Fractures, Myocardial Injury
Interventions
Accelerated medical clearance and surgery
Other
Lead sponsor
Population Health Research Institute
Other
Eligibility
45 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
23
States / cities
Chandler, Arizona • Davis, California • Irvine, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 31, 2026, 4:36 AM EDT
Not yet recruiting Phase 2 Interventional

Tailored Neoadjuvant Chemoimmunotherapy for Stage I TNBC

NCT07786428
Site status not listed — check the official record
View directory record Official record
Conditions
Triple-Negative Breast Cancer (TNBC)
Interventions
Pembrolizumab, Paclitaxel (Chemotherapy), Carboplatin
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 31, 2026, 4:36 AM EDT
Not yet recruiting Not applicable Interventional

Combination Versus Alone Liposomal Bupivacaine Blocks in Minimally Invasive Thoracic Surgery-1

NCT07254650
Site status not listed — check the official record
View directory record Official record
Conditions
Lung Cancer (Diagnosis)
Interventions
Arm 1 "LipoB-I": Liposomal Bupivacaine via Multi-Level Intercostal Nerve Block, Arm 2 "LipoB-S": Liposomal Bupivacaine via Serratus Anterior Plane Block, Arm 3 "LipoB-C": Liposomal Bupivacaine Administered via Combination Block
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 31, 2026, 4:36 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

NCT04544293
Site status not listed — check the official record
View directory record Official record
Conditions
Autoimmune Pulmonary Alveolar Proteinosis
Interventions
Molgramostim, Placebo, Molgramostim Open-label
Drug
Lead sponsor
Savara Inc.
Industry
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
16
States / cities
Little Rock, Arkansas • Los Angeles, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 31, 2026, 4:36 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Influence of Obesity on Oxalate Metabolism and Handling in Calcium Oxalate Stone Formers

NCT04333745
Site status not listed — check the official record
View directory record Official record
Conditions
Kidney Stone
Interventions
Controlled Diet, Carbon-13 Oxalate and Sucralose Ingestion
Other · Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
2
States / cities
Birmingham, Alabama • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 31, 2026, 4:36 AM EDT
Recruiting Phase 3 Interventional

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

NCT03959085
Status at this site: Recruiting
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia, Mixed Phenotype Acute Leukemia, Testicular Leukemia
Interventions
Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Calaspargase Pegol, Computed Tomography, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Inotuzumab Ozogamicin, Leucovorin Calcium, Magnetic Resonance Imaging, Mercaptopurine, Methotrexate, Pegaspargase, Positron Emission Tomography, Prednisolone, Prednisone, Questionnaire Administration, Radiation Therapy, Thioguanine, Vincristine Sulfate
Procedure · Biological · Drug + 2 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
365 Days to 25 Years
Enrollment
5,951 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2032
U.S. locations
203
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 155 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 31, 2026, 4:36 AM EDT
Recruiting Phase 3 Interventional

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

NCT06958328
Status at this site: Recruiting
View directory record Official record
Conditions
Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Capecitabine, Computed Tomography, Dose-escalated Radiation Therapy, Fluorouracil, Gemcitabine, Irinotecan Hydrochloride, Irinotecan Sucrosofate, Leucovorin Calcium, Magnetic Resonance Imaging, Nab-paclitaxel, Observation Activity, Oxaliplatin, Positron Emission Tomography, Questionnaire Administration, Radiation Therapy, Tumor Treating Fields Therapy
Procedure · Drug · Radiation + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
332
States / cities
Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 252 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 31, 2026, 4:36 AM EDT
Recruiting Phase 3 Interventional

Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

NCT05304585
Status at this site: Recruiting
View directory record Official record
Conditions
Embryonal Rhabdomyosarcoma, Fusion-Negative Alveolar Rhabdomyosarcoma, Spindle Cell/Sclerosing Rhabdomyosarcoma
Interventions
Biopsy Procedure, Bone Scan, Computed Tomography, Cyclophosphamide, Dactinomycin, Magnetic Resonance Elastography, Positron Emission Tomography, Radiation Therapy, Vincristine
Procedure · Drug · Biological + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
166
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 129 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 31, 2026, 4:36 AM EDT
Recruiting Phase 2 Interventional

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

NCT04322318
Status at this site: Recruiting
View directory record Official record
Conditions
Anaplastic Kidney Wilms Tumor, Recurrent Kidney Wilms Tumor, Stage II Kidney Wilms Tumor, Stage III Kidney Wilms Tumor, Stage IV Kidney Wilms Tumor
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Scan, Carboplatin, Computed Tomography, Cyclophosphamide, Doxorubicin, Etoposide, Ifosfamide, Irinotecan, Magnetic Resonance Imaging, Positron Emission Tomography, Radiation Therapy, Surgical Procedure, Topotecan, Transabdominal Ultrasound, Vincristine, X-Ray Imaging
Procedure · Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
178
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 138 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 31, 2026, 4:36 AM EDT

About this UT Southwestern Medical Center institution page

What this page lists
ClinicalTrials.gov records that list UT Southwestern Medical Center in Dallas, TX as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.